Smart soles could track walking trouble in nerve disease
NCT ID NCT05492604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether special insoles with pressure sensors (FEETME®) can accurately measure walking speed in people with CIDP, a nerve condition that causes walking difficulties. Researchers compared the insoles to a standard walkway system in 18 adults aged 18-75 with CIDP. The study was terminated early, so results are limited, but if validated, these insoles could provide a convenient way to monitor gait at home.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the smart insoles prove accurate, they could offer a simple, at-home way to track walking problems in CIDP, helping doctors adjust treatments more easily.
- What could go wrong
- This was a small, early-stage study that was terminated, so results are limited. The technology may not be reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
18 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Jun 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients of both sexes, aged 18 to 75 years old. * Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) defined or probable according to the EFNS/PNS (European Federation of Neurological Societies/Peripheral Nerve Society) diagnostic criteria proposed in 2010. * Patients treated with intravenous polyvalent immunoglobulins. * Patients with gait impairment related to CIDP, not requiring technical assistance, with an ONLS (Overall Neuropathy Limitations Scale) score of 1 or 2/7 on the lower limbs at inclusion. * Patients affiliated to or benefiting from a social security scheme. * Patients giving their free and informed consent to participate after information about the research. Exclusion Criteria: * Pregnant or breastfeeding women. * Patients placed under guardianship, curatorship or safeguard of justice.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic inflammatory demyelinating polyneuropathy (CIDP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pellegrin Hospital
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can wearable sensors and walking tests reliably track nerve damage?
- Experimental cell therapy takes aim at Hard-to-Treat autoimmune diseases
- New hope for CIDP patients: early access to efgartigimod drug
- New study aims to unravel nerve mysteries in rare diseases
- Engineered immune cells take on multiple sclerosis and other autoimmune brain diseases